TriangleHEALTH PROFESSIONAL · SOURCE READING
Epcoritamab
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Epcoritamab is a CD20-directed BiTE. It is given subcutaneously every 28 days until disease progression or unacceptable toxicity with weekly step-up dosing during cycle 1.
Evidence (epcoritamab):
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
Source links and citations
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
With a median follow-up of 10.7 months, the overall response rate was 63.1% (95% CI, 55.0%–70.6%), and the complete response rate was 38.9% (95% CI, 31.2%–46.9%).[40][Level of evidence C3]
Source links and citations
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
The median PFS was 4.4 months (95% CI, 3.0–7.9).
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
The median OS was not reached (95% CI, 11.3–not reached).
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
Cytokine release syndrome occurred in 49.7% of patients, and it was grade 3 or higher in 2.5% of patients. Immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 6.4% of patients, and it was grade 3 or higher in 0.6% of patients.
A phase I/II trial (NCT03625037) included 157 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[40]
Results were not significantly different among 61 recipients of prior CD19-directed CAR T-cell therapy.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice